Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older-Reference-Cited by-同舟云学术

Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older

Published:2008-05-01 Issue:9 Volume:112 Page:2021-2029
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Simon George R.,Extermann Martine,Chiappori Alberto,Williams Charles C.,Begum Mubeena,Kapoor Rachna,Haura Eric B.,Ismail-Khan Roohi,Schell Michael J.,Antonia Scott J.,Bepler Gerold

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.23360/fullpdf

Reference51 articles.

1. Cancer Statistics, 2007

2. First-line chemotherapy for NSCLC: an overview of relevant trials

3. Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non‐small cell lung cancer harboring EGFR mutations ( JMTO LC12 ‐01);Thoracic Cancer;2022-05-13

2. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade;Breast Cancer Research;2017-08-04

3. Cancer, obesity, and diabetes: TKIs exert multiple effects on glucose homeostasis;Nature Reviews Clinical Oncology;2017-04-19

4. Simulating the contribution of a biospecimen and clinical data repository in a phase II clinical trial: A value of information analysis;Statistical Methods in Medical Research;2016-07-11

5. Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma;BioMed Research International;2014